Anti-Mouse RGMb Antibody (307.9D1) 

Anti-Mouse RGMb Antibody (307.9D1) is a rat-derived IgG2a κ type antibody inhibitor, targeting to mouse RGMb. Anti-Mouse RGMb Antibody (307.9D1) blocks RGMb binding to PD-L2. Anti-Mouse RGMb Antibody (307.9D1) can be used for the researches of cancer inflammation and immunology, such as acute myeloid leukemia (AML) and graft versus-host disease (GVHD)^[1][2][3][4].

Rat IgG2a kappa

Rat IgG2a kappa, Isotype Control

Mouse

RGMb

The antibody framework is stable, specific and adaptable, and has the ability to bind both antigens and endogenous immune receptors. Monoclonal antibodies have several derivatives, including bispecific antibodies, antibody-drug conjugates, and antibody fragments, and have significant effects in fields such as immunology and oncology. When designing inhibitory antibodies, considerations include identification of antigen-specific variable regions, choice of expression system, use of multispecific formats, and antibody derivatives based on fragmentation, oligomerization, or conjugation with other functional moieties^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Anti-Mouse RGMb Antibody (307.9D1) (100 μg, i.p., at days 7, 10, 13, 16 post tumor implantation) suppresses tumor growth in MC38 tumor mice models^[1].
Anti-Mouse RGMb Antibody (307.9D1) (450 μg before induction and 200 μg at 2 days after induction, i.p.) inhibits the development of respiratory tolerance and increases T cell proliferation and IL-4 production in ovalbumin-induced respiratory tolerance mice models^[2].
Anti-Mouse RGMb Antibody (307.9D1) (200 μg, i.p., every 3 days for 6 times) modestly delays the onset of demonstrable leukemia and mildly improves survival companied with anti-PD1 and anti-TIM3 in acute myeloid leukemia mice models^[3].
Anti-Mouse RGMb Antibody (307.9D1) (20 mg/kg, i.p., at days -1, 3 and 7) inhibits graft versus-host disease with improved survival in NSG mice^[4].
Anti-Mouse RGMb Antibody (307.9D1) (200 μg/mouse, i.p., at days -1, 3 and 7) protects mice against weight loss and death in Dextran sulfate sodium salt (DSS) (HY-116282C)-induced colitis mice models^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

68799  [NCBI]

Q7TQ33 / NP_848730.2

ELISA, FACS, Functional assay, Research in vivo

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

150 kDa

[Anti-Mouse RGMb Antibody (307.9D1)]

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Park JS, et al. Targeting PD-L2-RGMb overcomes microbiome-related immunotherapy resistance. Nature. 2023 May;617(7960):377-385.  [Content Brief]

  [2]. Xiao Y, et al. RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance. J Exp Med. 2014 May 5;211(5):943-59.  [Content Brief]

  [3]. Stroopinsky D, et al. Leukemia vaccine overcomes limitations of checkpoint blockade by evoking clonal T cell responses in a murine acute myeloid leukemia model. Haematologica. 2021 May 1;106(5):1330-1342.  [Content Brief]

  [4]. Pérez-Cruz M, et al. Immunoregulatory effects of RGMb in gut inflammation. Front Immunol. 2022 Nov 7;13:960329.  [Content Brief]